title: Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
abstract: BACKGROUND
  A Phase II confirmatory multicenter trial was performed to evaluate a combination of epirubicin, cisplatin, and continuous infusion 5-fluorouracil (ECF) in treating patients with advanced gastric cancer.
  
  
  METHODS
  Fifty-three patients with locally advanced (n = 7) or metastatic (n = 46) gastric cancer received a dose of epirubicin (50 mg/m2) and cisplatin (60 mg/m2) intravenously every 21 days for eight cycles with 5-fluorouracil (200 mg/m2/day) by intravenous continuous infusion for 21 consecutive weeks, administered through a central line using an external pump.
  
  
  RESULTS
  Eight complete responses and 22 partial responses (response rate = 56%, 95% confidence interval +/- 13) were achieved. Twelve patients had stable disease. The median duration of response was 10 months (range, 3-21 months), and the median survival for all the patients was 9+ months (range, 2-28 months). Overall toxicity, which was primarily hematologic, was mild with only three patients requiring hospitalization for neutropenic fever. No death due to toxicity occurred.
  
  
  CONCLUSIONS
  This study found that the ECF regimen is substantially active in treating patients with advanced gastric cancer and has a favorable pattern of toxicity. This schedule clearly deserves randomized comparative trials for palliation of metastatic disease and for adjuvant purposes.
authors.affiliation: Servizio di Oncologia, Spedali Civili, Brescia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Zaniboni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: G
authors.initials: G
authors.lastname: Marini
authors.forename: G
authors.initials: G
authors.lastname: Pancera
authors.forename: G
authors.initials: G
authors.lastname: Giaccon
authors.forename: E
authors.initials: E
authors.lastname: Piazza
authors.forename: A
authors.initials: A
authors.lastname: Signaroldi
authors.forename: W
authors.initials: W
authors.lastname: Legnani
authors.forename: G
authors.initials: G
authors.lastname: Luporini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil